Background: The term tanatophorik comes from the Greek word thanatophorus which means "innate death" or "bearing death". The problem that underlies this disease is the process of bone formation. This disease is associated with an autosomal dominant inherited mutation of the fibroblast growth factor 3 receptor (FGFR3) gene on the arm of chromosome 4 (4p16.3). Because FGFR3 is the main modulator in bone formation, the typical clinical features of this disease include shortening of the extremities, curved femur, clover-like skull and narrowing of the thoracic cavity.Tanatophoric dysplasia is a skeletal disorder that is "lethal" or deadly. The deaths occurred due to respiratory failure caused by reduced chest cavity capacity, hypoplastic lungs and / or brainstem compression.Destination: Reported a case of thanatophoric dysplasiaMethod: Case Report Case Report: Case 33 years old woman, with preterm parturient G1P0A0H0 35-36 weeks 1 latent phase + history of 2x laparotomy + suspected fetal tanatophoric dysplasia. On ultrasound examination, it was found that BPD = 9.14 cm; AC = 30.56 cm; HC = 32.05 cm; FL = 2.55 cm; AFI; 9.06cm; SDAU = 1.72 cm. The presence of frontal bosing, saddle nose and micromilia (proximal, distal, phalanges) was found. The patient was planned for vaginal delivery and the progress of labor was followed. Patients provided informed consent regarding the possibility of fetal death during labor and after birth. During the active phase of the labor process, hypotony uterine innersia occurs and oxytocin drip is performed to accelerate labor. The baby was born male, weight 2175 grams, body length 34 cm and A / S: 1/0. Postmortem physical examination revealed macroscopic findings of tanatophoric dysplasia infants such as hypertelorism, low nasal bridge, cranio-facial disproportion. Narrow chest with protruding abdomen and short, bent limbs.Conclusion: Tanatophoric dysplasia is "lethal" skeletal dysplasia. Careful prenatal examination is required in diagnosis and termination of pregnancy. Keywords: Thanatophoric dysplasia, prenatal diagnosis
BACKGROUND: Cervical cancer was the fourth common women cancer in the world and the second most in Indonesia. Chemotherapy has been evaluated as a therapy strategy to treat cervical cancer stage IB2 and IIA2 prior the radical hysterectomy. Neoadjuvant chemotherapy was still being a controversy for the chemotherapy resistance patient and will delay the definitive therapy. A marker is needed to identify patient which more relatively resistant to chemotherapy. Squamous cell carcinoma (SCC) type was known to have a better response to neoadjuvant chemotherapy than non-SCC (nSCC) type, but they are no studies at Dr. M. Djamil Padang General Hospital yet on this matter before. OBJECTIVE: The objectives of the study were to obtain the relationship between histopathology type and neoadjuvant chemotherapy response for cervical cancer stage IB2 and IIA2. METHODS: This cohort analytic study conducted at Dr. M Djamil Padang Hospital which obtained 35 samples of stage IB2 and IIA2 cervical cancer patients whom treated with neoadjuvant chemotherapy. Results of histopathology are based on biopsy at diagnosis done for cervical cancer and chemotherapy response is based on transrectal ultrasound examinations before and after given neoadjuvant chemotherapy with response evaluation criteria in solid tumors criteria. RESULTS: Complete response and partial response in the SCC and nSCC group were 32%–50%, while stable disease (SD) and progressive disease were 68% in the SCC group to 50% in the nSCC group. CONCLUSION: There was no significant relationship between histopathological type and neoadjuvant chemotherapy response for cervical cancer stage IB2 and IIA2 (p = 0.44).
AbstrakLatar belakang: Kanker serviks menempati urutan keempat di seluruh dunia dan urutan kedua di Indonesia yang paling umum terjadi pada wanita. Kemoterapi telah dievaluasi sebagai salah satu strategi pengobatan kanker serviks stadium IB2 dan IIA2. Namun penggunaan kemoterapi neoadjuvant masih kontroversi pada pasien yang resisten dengan kemoterapi. Hal ini akan menunda pemberian terapi definitif, sehingga sangat penting untuk menemukan penanda yang dapat mengidentifikasi pasien mana yang relatif lebih resisten terhadap kemoterapi. Tipe squamous cell carcinoma (SCC) diketahui memiliki respon kemoterapi neoadjuvant yang lebih baik dibandingkan dengan non-squamous cell carcinoma (nSCC) namun belum ada penelitian yang dilakukan di RSUP M Djamil Padang mengenai hal ini sebelumnya. Tujuan: Untuk melihat Hubungan Tipe Histopatologi Dengan Respon Kemoterapi Neoadjuvant Pada Kanker Serviks Stadium IB2 Dan IIA2. Metode: Penelitian ini merupakan studi analitik cohort yang dilakukan di RSUP Dr. M. Djamil Padang pada 35 sampel pasien kanker serviks stadium IB2 dan IIA2 yang diberikan kemoterapi neoadjuvant. Pengambilan sampel dilakukan dengan teknik consecutive sampling. Data meliputi hasil gambaran histopatologi serta hasil pemeriksaan ultrasonografi sebelum dan sesudah diberikan kemoterapi neoadjuvant. Analisis data mengunakan uji Chi-Square. Hasil: CR+PR pada kelompok SCC adalah sebesar 32% dan NSCC adalah 50%, sedangkan SD+PD adalah sebesar 68 % pada kelompok SCC dan 50% pada kelompok NSCC. Kesimpulan: Tidak terdapat hubungan yang bermakna antara tipe histopatologi dengan respon kemoterapi neoadjuvant pada kanker serviks stadium IB2 dan IIA2 (p=0.44). Kata kunci: histopatologi, kemoterapi, kanker serviks Pendahuluan Kanker serviks merupakan keganasan yang menyerang serviks atau leher rahim, hal ini terjadi karena adanya suatu perubahan sel leher rahim normal menjadi sel abnormal yang kemudian mengalami proliferasi yang tidak terkendali. Penyebab utamanya adalah infeksi satu atau lebih virus HPV (Human Papiloma Virus) tipe onkogenik dan banyak diderita oleh wanita yang telah menikah atau aktif berhubungan seksual. 1 Kanker serviks adalah jenis kanker nomor empat paling sering pada perempuan di dunia dan merupakan kanker terbanyak kedua pada wanita usia 15 sampai 44 tahun di dunia. 2
Ovarian borderline tumors are a group of pathologic tumors that exhibit a higher proliferative activity when compared to benign tumors. Due to the absence of a screening method, ovarian cancer is often diagnosed when the patient already has a complaint, or at an advanced stage. A 24-year-old patient was diagnosed with cystic ovarian neoplasm, the results of physical examination and support support the possibility of malignancy. In this patient, a left salphingo-oophorectomy was chosen instead of cystectomy, this was done considering the size of the tumor mass was large enough so that the normal tissue of the ovary was estimated to be almost absent. From the results of the PA laboratory is cystadenoma multiloculare ovarii mucinosum borderline with this microinvation. The patient found massive ascites which could be classified as high risk. In high-risk stage I borderline ovarian tumors, laparotomy should include hysterectomy and bilateral salpingo-oophorectomy. However, because the patient still expects reproductive function, conservative surgery can be performed by only performing unilateral salpingo-oophorectomy, omentum (left ovary and left tube), left inguinal gland and peritoneal rinses. Additional platinum-based chemotherapy such as carboplatine for 3-6 cycles may be indicated in high-risk patients such as this case. (left ovary and left tube) omentum, left inguinal gland and peritoneal rinses. Additional platinum-based chemotherapy such as carboplatine for 3-6 cycles may be indicated in high-risk patients such as this case. (left ovary and left tube) omentum, left inguinal gland and peritoneal rinses. Additional platinum-based chemotherapy such as carboplatine for 3-6 cycles may be indicated in high-risk patients such as this case.Keywords: Borderline ovarian tumor, conservative surgery
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.